Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancerCarlos L Arteaga, Anne O'Neill, Stacy L Moulder, et al.
Breast Cancer Research and Treatment|April 13, 2019
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)Luis Baez-Vallecillo, Akshara S Raghavendra, Kenneth R Hess, et al.
The Oncologist|March 19, 2017
Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer SubtypeRosalind P Candelaria, Roland L Bassett, William Fraser Symmans, et al.
BMC Cancer|September 24, 2016
A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancerSirwan M Hadad, Lee B Jordan, Pankaj G Roy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)Stacy L Moulder, Virginia F Borges, Tara Baetz, et al.
Breast Cancer Research and Treatment|July 21, 2014
Leptomeningeal disease and breast cancer: the importance of tumor subtypeSausan Abouharb, Joe Ensor, Monica Elena Loghin, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Cancer|January 7, 2010
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancerStacy L Moulder, Frankie A Holmes, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast CancerIman Doostan, Cansu Karakas, Mehrnoosh Kohansal, et al.
Molecular Cancer Therapeutics|May 17, 2011
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activitySiqing Fu, Aung Naing, Stacy L Moulder, et al.
Pageof 9